GET DAILY SIGNALSWhy Is RenovoRx (RNXT) Stock Down -15.55% Today?
Key Takeaways
- Shares of RNXT fell roughly 15.5% in Thursday's session, dropping from a prior close of $1.19 to about $1.01.
- The primary catalyst was a third-quarter earnings miss, with the company reporting a wider-than-expected net loss per share.
- Slowing sequential revenue growth and a tougher fourth-quarter setup added to the selling pressure despite a headline revenue beat.
- Elevated operating expenses tied to a commercial build-out weighed on the bottom line and raised questions about the path to profitability.
- Traders are now watching the fourth-quarter revenue trajectory and any updates on the company's pivotal TIGeR-PaC clinical readout.
- For deeper analysis of Price Targets, Earnings, and Forecast data, explore the dedicated pages for RNXT.
- Looking for automated trading ideas? Explore Trending AI Robots to see which AI-driven strategies are performing best under current market conditions.
Opening Summary
RenovoRx, Inc. (RNXT), a clinical-stage and commercial life-sciences company focused on targeted oncology therapies and its FDA-cleared RenovoCath local drug-delivery device, saw its stock tumble on Thursday. Shares dropped approximately 15.55%, falling from Wednesday's close of $1.19 to about $1.01. The move was driven by the market's reaction to the company's third-quarter 2026 results, reported after the previous session's close, which featured an earnings miss even as revenue exceeded expectations.
Earnings Results and Guidance
The sharp decline in RNXT shares followed the release of third-quarter financial results. The company posted a net loss of $0.08 per share, worse than the consensus estimate of a $0.05 loss, marking a clear earnings miss. While revenue reached a record $1.07 million, up roughly 300% year over year and slightly ahead of the roughly $1.05 million consensus, investors focused on the bottom-line shortfall and the underlying quality of growth.
Management reaffirmed full-year 2026 revenue guidance of $3.75 million to $4.25 million. However, that range implies a meaningful acceleration in the fourth quarter, a reacceleration that the company's recent trajectory has not yet demonstrated. This tension between a strong headline growth rate and fading sequential momentum became the central concern for investors.
Slowing Sequential Growth
Beneath the impressive year-over-year figures, the quarter's sequential growth curve bent sharply lower. Revenue rose only about 17% from the second quarter's $909,000, compared with sequential growth of roughly 61% in the second quarter and 136% in the first. The deceleration raised questions about whether the commercial ramp can sustain its earlier pace, contributing to the negative market reaction.
Rising Costs and Margin Pressure
The results also highlighted a rising cost base. Selling, general, and administrative expenses climbed to about $2.9 million from $1.7 million a year earlier as the company funded its commercial infrastructure build-out, while research and development spending declined as clinical trial enrollment wound down. Reported gross margin slipped to 82.4% from about 84% in the prior quarter, partly reflecting the conversion of trial devices to commercial use at zero gross margin. The widening GAAP net loss, amplified by a non-cash warrant-liability charge, underscored that the company remains unprofitable as it scales.
Market Context and Trading Activity
The sell-off in RNXT reflects an earnings-driven move rather than broad-market weakness. Small-cap biotech and medtech names often see outsized reactions to quarterly results, particularly when a report raises concerns about the durability of a commercial launch. Trading in RNXT was heavy relative to recent sessions as investors digested the mixed report, with the stock giving back gains built up ahead of the earnings release. The move pushed the shares toward the lower end of their recent trading range.
What Comes Next for RNXT
Looking ahead, investors will watch whether RNXT can reaccelerate revenue in the fourth quarter to meet its reaffirmed full-year guidance. The company's active commercial cancer-center count rose to 26 from 21, and its total commercial funnel grew to more than 65 centers, suggesting a foundation for continued growth, but conversion of the pipeline remains a key variable. Longer term, the pivotal Phase III TIGeR-PaC trial, which completed enrollment in August, is expected to deliver top-line overall survival data in the second half of 2027. Risks include the company's reliance on future financing, its concentrated adoption base, and the extended wait for pivotal clinical evidence.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a range of approaches to explore. If you are interested in automated, data-driven trading ideas, consider reviewing the Trending AI Robots page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RNXT's Stochastic Oscillator remains in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RNXT's RSI Oscillator exited the oversold zone, 28 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for RNXT just turned positive on October 23, 2026. Looking at past instances where RNXT's MACD turned positive, the stock continued to rise in 40 of 48 cases over the following month. The odds of a continued upward trend are 83%.
Following a +3.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNXT advanced for three days, in 200 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNXT as a result. In 86 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
RNXT moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RNXT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNXT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
RNXT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RNXT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. RNXT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.981) is normal, around the industry mean (2.788). P/E Ratio (-3.839) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (31.250) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNXT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement